<DOC>
	<DOCNO>NCT00427999</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , tolerability safety multi-targeted therapy patient hormone-refractory prostate cancer .</brief_summary>
	<brief_title>Combined Antiinflammatory Angiostatic Therapy Patients With Hormone-refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm prostate carcinoma , proven progression primary hormone therapy ( surgical medicinal castration ) . Patients must increase PSA level ( within 3 month prior enrollment ) least two consecutively increase PSA level . PSA value inclusion must least 5 ng/ml At least 18 year age . At least capable self care least 50 % waking hour ( ECOG performance status 0 2 ) , adequate bone marrow function lab result . Exclusion criterion : Change hormone therapy within 6 week prior inclusion Prior chemotherapy Therapy Imatinib , therapy inhibitor tyrosinkinase . Second neoplasm diagnose within 5 year study start . Patients require therapy warfarin Known diagnosis HIV , hepatitis B , hepatitis C infection . Severe , unstable , uncontrolled medical disease would confound diagnosis evaluation require protocol , include severe cardiac insufficiency Surgical therapy within 4 week inclusion . Prior therapy isotope strontium rhenium . Radiation therapy &gt; 25 % bone marrow within 4 week inclusion . Treatment experimental substance within 30 day study start . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hormone-refractory</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>multitargeted</keyword>
	<keyword>tyrosinkinase</keyword>
</DOC>